《大行報告》里昂下調錦欣生殖(01951.HK)目標價至8.4元 評級「買入」
里昂發表研究報告指,錦欣生殖(01951.HK)是中國最大的私人輔助生殖服務(ARS)提供商,於2021財年的市場份額為4.8%。該行預計,中國的ARS市場將在2022至2025年錄得12%的年均複合增長率,又相信集團將透過併購和高端服務保持其在私人市場的領導地位。
該行預計,錦欣生殖將在2021至25年期間,收入年均複合增長率料達20%,每股盈利年均複合增長率料24%,維持其「買入」評級,認為其估值吸引,目標價則由9元下調至8.4元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.